Jazz Pharmaceuticals plc (JAZZ)
Free
No email, no account, no signup.
Pulling latest news for Jazz Pharmaceuticals plc…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Biopharmaceuticals for neuroscience and oncology
Market Cap
$13.3B
We're already tracking Jazz Pharmaceuticals plc — here are the latest events we've registered
Recent News
- On May 5, 2026, Jazz Pharmaceuticals reported first-quarter 2026 total revenues of $1.1 billion, a 19% increase year-over-year. The company announced that the FDA granted Priority Review for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma, with a PDUFA date of August 25, 2026. Management also reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.50 billion.
Want to know how this news affects Jazz Pharmaceuticals plc? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Jazz Pharmaceuticals plc will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.